Efficacy and safety of lacosamide in the treatment of status epilepticus in a patient with comorbidities.


Journal

Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064

Informations de publication

Date de publication:
30 04 2021
Historique:
received: 21 11 2019
accepted: 22 02 2020
entrez: 4 5 2021
pubmed: 5 5 2021
medline: 29 6 2021
Statut: epublish

Résumé

Efficacy, safety and tolerability of lacosamide in the treatment of status epilepticus are well described. However, other evidence of its pharmacologic profile in elderly patients with other comorbidities seems warranted. We describe the case of an 80 year-old woman with an history of arterial hypertension, ischemic cardiomyopathy, COPD, CKD, previous laryngeal cancer, a stoma positioning for diverticular disease and previous surgery for a left frontal meningioma. Since then, the patient developed focal epilepsy and she was on levetiracetam and valproic acid therapy. The patient was admitted to our department for a focal status epilepticus characterized by non-fluent aphasia and right facio-brachial clonic movements. She also presented with aspiration pneumonia and started intravenous antibiotic treatment. After failure of a first-line antiepileptic drug, lacosamide intravenous treatment was started, with complete reversal of the clinical picture. EEG then showed focal slow waves mixed to interictal epileptiform discharges over the left fronto-temporal regions. The patient was then discharged home with an oral lacosamide treatment and at 3 months she was seizure-free. Our case report confirms the efficacy of lacosamide in status epilepticus, highlighting its safety and tolerability in an elderly and fragile patient with multiple comorbidities and drug therapy.

Identifiants

pubmed: 33944850
doi: 10.23750/abm.v92iS1.9043
pmc: PMC8142756
doi:

Substances chimiques

Anticonvulsants 0
Levetiracetam 44YRR34555
Lacosamide 563KS2PQY5

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2021090

Références

BMC Neurol. 2016 Nov 5;16(1):213
pubmed: 27816063
Epilepsia. 2015 Oct;56(10):1515-23
pubmed: 26336950
Epilepsy Behav. 2017 Oct;75:86-89
pubmed: 28834781
J Neurol Neurosurg Psychiatry. 2006 May;77(5):611-5
pubmed: 16614020
Epilepsia. 2013 Jan;54(1):58-65
pubmed: 22708895
Epilepsia. 2017 Jun;58(6):933-950
pubmed: 28295226
Ther Adv Neurol Disord. 2017 Feb;10(2):103-126
pubmed: 28382109
Epilepsia. 2012 May;53(5):e89-92
pubmed: 22462650
Lancet Neurol. 2017 Jan;16(1):43-54
pubmed: 27889312
Epilepsia. 2018 Oct;59 Suppl 2:140-143
pubmed: 30159881
Epilepsia. 2009 Mar;50(3):443-53
pubmed: 19183227

Auteurs

Alfredo Paolo Mascolo (AP)

UOC Neurologia, Department of Systems Medicine, University of Tor Vergata. alfrymaskred@gmail.com.

Federico Marrama (F)

UOC Neurologia, Department of Systems Medicine, University of Tor Vergata. federico.marrama@gmail.com.

Nicola Biagio Mercuri (NB)

UOC Neurologia, Department of Systems Medicine, University of Tor Vergata. mercurin@uniroma2.it.

Fabio Placidi (F)

UOC Neurologia, Department of Systems Medicine, University of Tor Vergata. flacidi@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH